title: Evaluation of Docetaxel-Sensitive and Docetaxel-Resistant Proteomes in PC-3 Cells.
abstract: OBJECTIVE
  Docetaxel was the first drug with proven survival benefit in men with castration-resistant prostate cancer. Acquired resistance to docetaxel precedes fatality in castration-resistant prostate cancer. The aims of this study were to evaluate docetaxel-sensitive and docetaxel-resistant proteomes in PC-3 cells, and to investigate the molecular mechanism of docetaxel-resistant PC-3 cells.
  
  
  METHODS
  Docetaxel-resistant PC-3 cells were developed by docetaxel dose escalation. The global profiling of the protein expression was investigated in docetaxel-sensitive and docetaxel-resistant proteomes in PC-3 cells using 2-dimensional polyacrylamide gel electrophoresis/matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
  
  
  RESULTS
  Forty-nine differential proteins were found in docetaxel-resistant PC-3 cells in comparison with docetaxel-sensitive PC-3 cells. Expression in 29 proteins was upregulated, whereas expression in 20 proteins was downregulated. ATP synthase and galectin-1 were involved in the formation of tumor vessels; calreticulin, cathepsin D, and cofilin were involved in tumor metastasis, and GRP78 (78-kDa glucose-regulated protein) and microtubule-associated protein-6 were involved in drug resistance of tumor.
  
  
  CONCLUSIONS
  It is suggested that a proteomic expression difference exists between docetaxel-sensitive and docetaxel-resistant PC-3 cells, which would be helpful for further understanding the molecular mechanisms of docetaxel resistance in PC-3 cells.
authors.affiliation: Department of Urology, The Second Hospital of Shandong University, Jinan, China.
authors.forename: Shulu
authors.initials: S
authors.lastname: Zu
authors.forename: Weiming
authors.initials: W
authors.lastname: Ma
authors.forename: Pan
authors.initials: P
authors.lastname: Xiao
authors.forename: Yazhou
authors.initials: Y
authors.lastname: Cui
authors.forename: Tianjia
authors.initials: T
authors.lastname: Ma
authors.forename: Chunwen
authors.initials: C
authors.lastname: Zhou
authors.forename: Huaiqiang
authors.initials: H
authors.lastname: Zhang
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry* / Q000627:therapeutic use; D037282:Calreticulin / Q000378:metabolism; D002402:Cathepsin D / Q000378:metabolism; D045744:Cell Line, Tumor; D051338:Cofilin 1 / Q000378:metabolism; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D015180:Electrophoresis, Gel, Two-Dimensional; D000091342:Endoplasmic Reticulum Chaperone BiP; D015972:Gene Expression Regulation, Neoplastic; D006360:Heat-Shock Proteins / Q000378:metabolism; D006801:Humans; D020128:Inhibitory Concentration 50; D008297:Male; D013058:Mass Spectrometry; D009362:Neoplasm Metastasis; D064129:Prostatic Neoplasms, Castration-Resistant / Q000378:metabolism; D020543:Proteome; D040901:Proteomics; D043823:Taxoids / Q000737:chemistry* / Q000627:therapeutic use; D015854:Up-Regulation
chemical_list: D000970:Antineoplastic Agents; C576483:CALR protein, human; D037282:Calreticulin; D051338:Cofilin 1; D000091342:Endoplasmic Reticulum Chaperone BiP; C000717247:HSPA5 protein, human; D006360:Heat-Shock Proteins; D020543:Proteome; D043823:Taxoids; D000077143:Docetaxel; C533922:CTSD protein, human; D002402:Cathepsin D